Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
National Institutes of Health Clinical Center (CC)
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
European Myeloma Network B.V.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
GlaxoSmithKline
Fred Hutchinson Cancer Center
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
Augusta University
Washington University School of Medicine
University of California, San Francisco
Peking University People's Hospital
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Celgene
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Affiliated Hospital to Academy of Military Medical Sciences
Dartmouth-Hitchcock Medical Center
Essen Biotech
M.D. Anderson Cancer Center
Juno Therapeutics, a Subsidiary of Celgene
University of Arkansas
Medical College of Wisconsin
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
M.D. Anderson Cancer Center
Fate Therapeutics
Case Comprehensive Cancer Center
Mayo Clinic
Thomas Jefferson University
Thomas Jefferson University
Northside Hospital, Inc.
Brown University
University of Rochester
Mayo Clinic
Affiliated Hospital to Academy of Military Medical Sciences
National Institutes of Health Clinical Center (CC)
GWT-TUD GmbH
Case Comprehensive Cancer Center
University of Arkansas
Mayo Clinic
Affiliated Hospital to Academy of Military Medical Sciences